Current monitoring guidelines recommend active monitoring of alertness every 30 minutes for 2 hours post-injection
Olanzapine depot injection is used for the maintenance treatment of schizophrenia in adults
2 and 4
Olanzapine Pamoate LAI is an atypical antipsychotic used in the maintenance treatment of schizophrenia
4 % of treated patients and requires a specific risk-management plan
It is proven to be effective in patients with schizophrenia in both acute and stable phases
オランザピン(英語: Olanzapine )は、非定型抗精神病薬の一つである。1996年に発売された。日本国内では2000年に統合失調症の治療薬として承認され、のちに双極性障害における躁症状(2010年)およびうつ症状(2012年)を改善する薬剤として追加承認された。 Olanzapine Zalasta, Zyprexa
LAIs show a similar safety profile to oral formulations of the relevant drug, with the exception of olanzapine pamoate, which can lead to rare cases of post-injection delirium/sedation syndrome (PDSS)
This includes information on what the medication is for, how to take it, possible side effects and safety information
Post-Injection delirium/sedation syndrome, a collection of signs and symptoms consistent with olanzapine overdose has been reported following injections of the extended-release IM suspension
tic-like (jerky) movements of the head, face, mouth, and neck
Olanzapine long-acting injection (LAI) for the treatment of schizophrenia was associated with a cluster of symptoms termed post-injection delirium/sedation syndrome (PDSS) in a small percentage (~2%) of patients during clinical trials
1 From 2000 to 2008, it has been observed that delirium/sedation syndrome (PDSS) occurred in approximately 0
It is available in multiple generic and brand versions
lack of coordination
In clinical trials, olanzapine LAI had a safety profile comparable with that of oral olanzapine, with the exception of the occurrence of adverse events (AEs) related to route of Post-injection delirium/sedation syndrome (PDSS), also known as post injection syndrome, is a serious adverse event observed in a small percentage of patients treated with olanzapine long-acting injection (LAI), following approximately 0